Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Cannabis sativa oil, particularly in formulations rich in cannabidiol (CBD), has scientific support for use in treating certain types of convulsions, especially those associated with severe epilepsy syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. The primary evidence comes from randomized, double-blind, placebo-controlled clinical trials that have demonstrated a significant reduction in seizure frequency among patients given highly purified CBD oil (approved as the drug Epidiolex in several countries). These studies have led to formal regulatory approval for pharmaceutical-grade CBD oil in the treatment of refractory epilepsy in children and adults.

Historically, cannabis extracts have been used in traditional medicine systems for convulsive disorders, but the modern scientific validation comes from recent decades of research. The anticonvulsant effects are attributed mainly to CBD, which is non-intoxicating and acts on the endocannabinoid system and other neural pathways to reduce neuronal hyperexcitability. It is important to note that not all cannabis sativa oils have standardized or sufficient levels of CBD for anticonvulsant effects, and the presence of THC (tetrahydrocannabinol) can pose additional risks.

In summary, the use of cannabis sativa oil, specifically CBD-rich extracts, for convulsions is supported by robust scientific evidence for certain forms of epilepsy, though its efficacy and safety in other types of convulsive disorders remain under investigation.

More about cannabis sativa oil
More about Convulsions

Other ingredients used for Convulsions

Other health conditions supported by cannabis sativa oil

Products containing cannabis sativa oil

Pure Encapsulations Hemp extract VESIsorb®